Episode Details

Lifewards Q1 2026 earnings show a dip in revenue to $3.9M, down from $5M last year, due to supply chain issues and manufacturing shifts. However, ReWalk personal exoskeletons saw an 11% increase to $1.6M, driven by better reimbursements and international sales. The company made strategic acquisitions, including Oratechs protein oral delivery platform and an upper body exoskeleton tech for stroke patients. Despite a one-time expense, non-GAAP operating expenses dropped 12% to $5.9M. Gross margins slipped due to tariffs and lower volumes, but cash increased to $11.4M. ReWalks Germany sales surged 25% QoQ, and theyre expanding Medicare Advantage coverage. Management expects AlterG backlog to clear in Q2-Q3, keeping full-year revenue flat. Lifeward aims for profitability by late 2026-2027, balancing MedTech growth with low-risk biotech bets.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b5ede4d8a0e2dd9d